Updated recommendations for the diagnosis and management of osteoporosis: A local perspective

Annals of Saudi Medicine

Volumn 31, Issue 2, 2011, Pages 111-128

  Raef, Hussein ^a   Al Bugami, Munira ^a   Balharith, Sakra ^a   Moawad, Mahmoud ^a   El Shaker, Mohammad ^a   Hussain, Aneela ^a   Al Shaikh, Ahmad ^a   Al Badawi, Ismail ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; ANTIESTROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; COLECALCIFEROL; CONJUGATED ESTROGEN; DENOSUMAB; ERGOCALCIFEROL; ESTROGEN; GLUCOCORTICOID; IBANDRONIC ACID; MEDROXYPROGESTERONE ACETATE; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID; STRONTIUM RANELATE; TAMOXIFEN; TESTOSTERONE; VITAMIN D; ZOLEDRONIC ACID;

ADOLESCENCE; AGED; ALGORITHM; BONE DENSITY; BONE MASS; BONE PAIN; BREAST CANCER; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY FAILURE; DEEP VEIN THROMBOSIS; DEMENTIA; DIAGNOSTIC PROCEDURE; DIARRHEA; DIGESTIVE SYSTEM ULCER; DIZZINESS; DRUG ABSORPTION; DRUG COST; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; ESOPHAGITIS; EVENING DOSAGE; FRACTURE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPERSENSITIVITY REACTION; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIC HEART DISEASE; JAW OSTEONECROSIS; LEG PAIN; LOW DRUG DOSE; MAINTENANCE THERAPY; MYALGIA; MYOPATHY; NAUSEA; NEPHROTOXICITY; ORGAN TRANSPLANTATION; ORTHOSTATIC HYPOTENSION; OSTEOGENESIS IMPERFECTA; OSTEOPENIA; OSTEOPOROSIS; PATIENT SELECTION; PHYSICIAN; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING; SIDE EFFECT; STROKE; THROMBOEMBOLISM; TREATMENT CONTRAINDICATION; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE; VITAMIN D DEFICIENCY;

AGE FACTORS; AGED; ALGORITHMS; BONE DENSITY CONSERVATION AGENTS; CALCIUM; FEMALE; FRACTURES, BONE; HUMANS; MALE; MASS SCREENING; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTORS; SAUDI ARABIA; SEX FACTORS; VITAMIN D;

EID: 79953179714     PISSN: 02564947     EISSN: 09754466     Source Type: Journal    
DOI: 10.4103/0256-4947.77502     Document Type: Review

References (113)

1. Raef H, Frayha HH, El-Shaker M, Al-Humaidan A, Conca W, Sieck U, et al. Recommendations for the diagnosis and management od osteoporosis: A local perspective. Ann Saudi Med 2004;24:242-52.
2. Cooper C, Campion G, Melton LJ. Hip fractures in the elderly: A worldwide projection. Osteoporos Int 1992;2:285-9.
3. NIH consensus development panel on osteoporosis prevention, diagnosis and therapy. South Med J 2001;94:569-73.
4. Brown JP, Josse RG. Scientific advisory council of the osteoporosis society of Canada. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002;167:S1-34. (Pubitemid 35365303)
5. NIH Consensus Development Panel on Osteoporosis. JAMA 2001;285:785-95.
6. Tzaphlidou M. Bone architechture: Collagen structure and calcium/phosphorus maps. J Biol Phys 2008;34:39-49.
7. Crabtree NJ, Kroger H, Martin A, Pols HA, Lorenc R, Nijs J, et al. Improving risk assessment: Hip geometry, bone mineral distribution and bone strength in hip fracture cases and controls: The Epos study. Osteoporosis Int 2002;13:48-54. (Pubitemid 34157831)
8. Crans GG, Silverman SL, Genant HK, Glass EV, Krege JH. Association of severe vertebral fractures with reduced quality of life. Arthritis Rheum 2004;50:4028-34.
9. Hasserius R, Karlsson MK, Nilsson BE, Redlund-Johnell I, Johnell O; European Vertebral Osteoporosis Study. Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: A 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporosis Int 2003;14:61-8. (Pubitemid 36267902)
10. Braithwaite RS, Col NF, Wong JB. Estimating hip fracture morbidity, mortality, and costs. J Am Geriatr Soc 2003;51:364-70. (Pubitemid 36348898)
11. El-Desouki MI. Osteoporosis in postmenopausal Saudi women using dual X-ray bone densitometry. Saudi Med J 1999;20:283-6.
12. Ghannam NN, Hammami, MM, Bakheet SM, Khan BA. Bone mineral density of the spine and femur in healthy Saudi females: Relation to vitamin D status, pregnancy, and lactation. Calci Tissue Int 1999;65:23-8 (Pubitemid 29293523)
13. Dougherty G, Al-Marzouk N. Bone density measured by dual-energy X absorptiometry in healthy Kuwaity women. Calcif Tissue Int 2001;68:225-9. (Pubitemid 32423108)
14. Ardawi MS, Maimany AA, Bahksh TM, Nasrat HA, Milaat WA, Al-Raddadi RM. Bone mineral density of the spine and femur in healthy Saudi Arabs. Osteoporos Int 2005;16:43-55. (Pubitemid 40193218)
15. Baddoura R, Okais J, Awada H. Incidence of fractures after the age of 50 years in the Lebanese population and implications in terms of osteoporosis, Rev Epidemiol Sante Publique 2001;49:27-32. (Pubitemid 34116530)
16. Al-Nuaim AR, Kremli M, Al-Nuaim M, Sandkgi S. Incidence of proximal femur fracture in an urbanized community in Saudi Arabia. Calcif Tissue Int 1999;56:536-8.
17. Gannagé-Yared MH, Chemali R, Yaacoub N, Halaby G. Hypovitaminosis D in a Sunny country: Relation to lifestyle and bone markers. J Bone Miner Res 2000;15:1856-62. (Pubitemid 30666240)
18. El-Hajj Fuleihan G, Nabulsi M, Choucair M, Salamoun M, Hajj Shahine C, Kizirian A, et al. Hypovitaminosis D in schoolchildren. Pediatrics 2001;107:E53.
19. Fonseca V, Tongia R, el-Hazmi M, Abu-Aisha H. Exposure to sunlight and vitamin D deficiency in Saudi Arabian women. Postgrad Med J 1984;60:589-91. (Pubitemid 14029193)
20. Taha SA, Dost SM, Sedrani SH. 25-Hydroxyvitamin D and total calcium: Extraordinarily low plasma concentrations in Saudi mothers and their neonates. Pediatr Res 1984;18:739-41. (Pubitemid 14093072)
21. Salamoun MM, Kizirian AS, Tannous RI, Nabulsi MM, Choucair MK, Deeb ME, et al. Low calcium and vitamin D intake in healthy children and adolescents and their correlates. Eur J Clin Nutr 2005;59:177-84. (Pubitemid 40268313)
22. Gannagé-Yared MH, Chemali R, Sfeir C, Maalouf G, Halaby G. Dietary calcium and vitamin D intake in an adult Middle Eastern population: Food sources and relation to lifestyle and PTH. Int J Vitam Nutr Res 2005;75:281-9. (Pubitemid 41291060)
23. Awumey EM, Mitra DA, Hollis BW, Kumar R, Bell NH. Vitamin D metabolism is altered in Asians Indians in the southern United States. J Clin Endocr Metab 1998;83:169-73. (Pubitemid 28498330)
24. Lips P, Duong T, Oleksik A, Black D, Cummings S, Cox D, et al. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: Baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab 2001;86:1212-21. (Pubitemid 32323007)
25. Raef H, Ingemansson S, Sobhi S, Sultan A, Ahmed M, Chaudhry M. The effect of vitamin D status on the severity of bone disease and on the other features of primary hyperparathyroidism (pHPT) in a vitamin D deficient region. J Endocrinol Invest 2004;27:807-12. (Pubitemid 40305509)
26. Nelson HD, Helfand M, Woolf SH, Allan JD. Screening for postmenopausal osteoporosis: A review of the evidence for the US. Preventive Service Task Force, Ann Intern Med 2002;137:529-41. (Pubitemid 35024625)
27. Wilkin TJ. Changing perceptions in osteoporosis. BMJ 1999;318:862-4.
28. Black DM, Steinbuch M, Palermo L, Dargent-Molina P, Lindsay R, Hoseyni MS, et al, An Assessment Tool for Predicting Risk in Postmenopausal Women, Osteoporos Int 2001;12:519-28. (Pubitemid 32777427)
29. WHO publication - Kanis JA, on behalf of the World Health Organisation Scientific Group. Assessment of osteoporosis at the primary health care level. WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield. (Available on request from the WHO Collaborating Centre or the IOF). 2007.
30. Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, et al. Cost-effective osteoporosis treatment thresholds: The United States perspective. Osteoporos Int 2008;19:437-47.
31. Akkus Z, Camdeviren H, Celik F, Gur A, Nas K. Determination of osteoporosis risk factors using a multiple logistic regression model in postmenopausal Turkish women. Saudi Med J 2005;26:1351-9. (Pubitemid 41479319)
32. Maalouf G, Gannagé-Yared MH, Ezzedine J, Larijani B, Badawi S, Rached A, et al. Middle East and North Africa consensus on osteoporosis. J Musculoskelet Neuronal Interact 2007;7:131-43. (Pubitemid 47249002)
33. Baddoura R, Arabi A, Haddad-Zebouni S, Khoury N, Salamoun M, Ayoub G, et al. Vertebral fracture risk and impact of database selection on identifying elderly Lebanese with osteoporosis. Bone 2007;40:1066-72. (Pubitemid 46386553)
34. U.S. Preventive Services Task Force, Screening for osteoporosis in postmenopausal women: Recommendations and rationale. Ann Intern Med 2002;137:526-8.
35. National Osteoporosis Foundation. Clinicians guide to prevention and treatment of osteoporosis. Available from: http://www.nof.org [Last accessed on 2008].
36. Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: Results from the national osteoporosis risk assessment. JAMA 2001;286:2815-22. (Pubitemid 33126923)
37. Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD. Indentification of Osteopenic Women at high risk of fracture: The OFELY study. J Bone Miner Res 2005;20:1813-9. (Pubitemid 41361882)
38. Khan AA. Premenopausal women and low bone density. Can Fam Physcian 2006;52:743-7.
39. Khan AA, Syed Z. Bone densitometry in premenopausal women. J Clin Densitom 2004;7:85-92.
40. Recommendations for the prevention and treatment of glucocorticoid- induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 2001;44:1496-503.
41. Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, et al. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: An update. J Intern Med 1998;244:271-92. (Pubitemid 28473991)
42. Devogelaer JP, Goemaere S, Boonen S, Body JJ, Kaufman JM, Reginster JY, et al. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: A consensus document of the Belgian Bone Club. Osteoporos Int 2006;17:8-19. (Pubitemid 41798023)
43. Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, et al. Teriparatide or Alendronate in glucocorticoid-induce osteoporosis. N Engl J Med 2007;357:2028.
44. Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, et al. for the HORIZON investigators Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): A multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009;373:1253-63.
45. Cohen A, Shane E. Osteoporosis after solid organ and bone marrow transplantation. Osteoporos Int 2003;14:617.
46. Rodino MA, Shane E. Osteoporosis after organ transplantation. Am J Med 1998;104:459-69. (Pubitemid 28274851)
47. Lyu DM, Zamora MR. Medical complications of lung transplantation. Proc Am Thorac Soc 2009;6:101-7.
48. Cohen A, Sambrook P, Shane E. Management of bone loss after organ transplantation. J Bone Miner Res 2004;19:1919-32 (Pubitemid 41103406)
49. Sambrook P, Henderson NK, Keogh A, MacDonald P, Glanville A, Spratt P, et al. Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Mineral Res 2000;15:1818-24. (Pubitemid 30666235)
50. De Sevaux RG, Hoitsma AJ, Corstens FH, Wetzels JF. Treatment with vitamin D and calcium reduces bone loss after renal transplantation: A randomized study. J Am Soc Nephrol 2002;13:1608-14. (Pubitemid 34579249)
51. Leidig-Bruckner, G, Hosch S, Dodidou, P, Ritschel D, Conradt C, Klose C, et al. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: A follow-up study. Lancet 2001;357:342-7. (Pubitemid 32128540)
52. Cahill BC, O'Rourke MK, Parker S, Stringham JC, Karwande SV, Knecht TP. Prevention of bone loss and fracture after lung transplantation: A pilot study. Transplantation 2001;72:1251-5. (Pubitemid 33026604)
53. Coco M, Glicklich D, Faugere MC. Prevention of bone loss in renal transplant recipients: A prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 2003;14:2669-76. (Pubitemid 37169355)
54. Kovac D, Lindic J, Kandus A, Bren AF. Prevention of bone loss in kidney graft recipients. Transplant Proc 2001;33:1144-5. (Pubitemid 32237783)
55. Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Mitterbauer C. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int 2003;63:1130-6. (Pubitemid 36315593)
56. Valero MA, Loinaz C, Larrodera L. Calcitonin and bisphosphonates treatment in bone loss after liver transplantation. Calcif Tissue Int 1995;57:15-9.
57. Grotz WH, Rump LC, Niessen A, Schmidt-Gayk H. Treatment of osteopenia and osteoporosis after kidney transplantation. Transplantation 1998;66:1004-8. (Pubitemid 28513378)
58. Cejka D, Benesch T, Krestan C, Roschger P, Klaushofer K, Pietschmann P, et al. Effect of teriparatide onearly bone loss after kidney transplantation. Am J Transplant 2008;8:1864-70.
59. Fleischer J, McMahon DJ, Hembree W, Addesso V, Longcope C, Shane E. Serum testosterone levels after cardiac transplantation. Transplantation 2008;85:834-9. (Pubitemid 351440747)
60. Aris RM, Neuringer IP, Weiner MA, Egan TM, Ontjes D. Severe osteoporosis before and after lung transplantation. Chest 1996;109:1176-83. (Pubitemid 26145652)
61. Desso V, Elmer D, Gaber AO. Bone mass in patients with type 1 diabetes mellitus awaiting simultaneous pancreas kidney transplant. Bone 1998;23:588.
62. Conley E, Muth B, Samaniego M, Lotfi M, Voss B, Armbrust M, et al. Bisphosphonates and bone fractures in long-term kidney transplant recipients. Transplantation 2008;86:231-7.
63. Spira A, Gutierrez C, Chaparro C, Hutcheon MA, Chan CK. Osteoporosis and lung transplantation: A prospective study. Chest 2000;117:476-81. (Pubitemid 30111601)
64. Cohen A, Addesso V, McMahon DJ, Staron RB, Namerow P, Maybaum S, et al. Discontinuing antiresorptive therapy one year after cardiac transplantation: Effect on bone density and bone turnover. Transplantation 2006;81:686-91.
65. Bianchi ML. Osteoporosis in children and adolescents. Bone 2007;41:486-95. (Pubitemid 47386052)
66. Ward LM, Glorieux FH. The spectrum of pediatric osteoporosis. In: Glorieux FH, Pettifor JM, Jüppner H, editors. Pediatric bone: Biology and diseases. San Diego, CA: Academic Press; 2003. p. 401-42.
67. Bone density evaluation in teens prevents future osteoporosis. Arch Pediatr Adolesc Med 2006;160:1026-32.
68. Bianchi ML. How to manage osteoporosis in children. Best Pract Res Clin Rheumatol 2005;19:991-1005. (Pubitemid 41748510)
69. Bachrach LK, Ward LM. Clinical review 1: Bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 2009;94:400-9.
70. Cromer B, Harel Z. Adolescents: At increased risk for osteoporosis? Clin Pediatr 2000;39:565-74.
71. Vetter U, Pontz B, Zauner E, Brenner RE, Spranger J. Osteogenesis imperfecta: A clinical study of the first 10 years of life. Calcif Tissue Int 1992;50:36-41.
72. Kauffman RP, Overton TH, Shiflett M, Jennings JC. Osteoporosis in children and adolescent girls: Case report of idiopathic juvenile osteoporosis and review of the literature. Obstet Gynecol Surv 2001;56:492-504. (Pubitemid 32734969)
73. Bianchi ML, Cimaz R, Bardare M, Zulian F, Lepore L, Boncompagni A, et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: A prospective multicenter study. Arthritis Rheum 2000;43:1960-6.
74. Shaw NJ, Bishop NJ. Bisphosphonate treatment of bone disease. Arch Dis Child 2005;90:494-9. (Pubitemid 40627446)
75. Saadi H, Boobes Y. Osteoporosis in renal failure: How accurate is the diagnosis and is there any role for bisphosphonates? Int J Diabetes Metab 2005;13:99-102. (Pubitemid 43025089)
76. Miller PD. Diagnosis and treatment of osteoporosis in chronic renal failure. Semin Nephrol 2009;29:144-55.
77. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation and classification of renal osteodystrophy: A position statement from kidney disease: Improving Global Outcomes (KDIGO). Kidney Int 2006;69:1945-53. (Pubitemid 43924257)
78. Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE. Safety and Efficacy of Risdronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: A pooled analysis of nine clinical trials. J Bone Mineral Res 2005;20:2015-115.
79. Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, et al. Alendronate treatment in women with normal to severely impaired renal function: An analysis for the fracture intervention trial. J Bone Mineral Res 2007;22:503-8. (Pubitemid 47457426)
80. Ishani A, Blackwell T, Jamal SA, Cummings SR, Ensrud KE; MORE Investigators. The effect of Raloxifene treatment in post-menopausal women with CKD. J Am Sco Nehprol 2008;19:1430-8.
81. Miller PD. Diagnosis and treatment of osteoporosis or fragility fractures in patients with chronic kidney disease. Osteoporosis: Clinical update- national osteoporosis foundation. Summer 2005.
82. MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, et al. Systematic review: Comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008;148:197-213. (Pubitemid 351665507)
83. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19:399-428.
84. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C, et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570-8. (Pubitemid 34925651)
85. Boonen S, Laan RF, Barton IP, Watts NB. Effect of osteoporosis treatments on risk of non-vertebral fractures: Review and meta-analysis of intention-to-treat studies. Osteoporos Int 2005;16:1291-8. (Pubitemid 41396959)
86. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial: Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45. (Pubitemid 29384151)
87. Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: Results from the MORE trial. Bone 2003;33:522-32. (Pubitemid 37222378)
88. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41.
89. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37. (Pubitemid 44050394)
90. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41. (Pubitemid 26411651)
91. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 1998;280:2077-82. (Pubitemid 29014065)
92. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial: Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52. (Pubitemid 29483192)
93. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women: Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40. (Pubitemid 32107641)
94. Chesnut IC, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9. (Pubitemid 41094364)
95. Delmas PD, Recker RR, Chesnut CH 3rd, Skag A, Stakkestad JA, Emkey R, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: Results from the BONE study. Osteoporos Int 2004;15:792-8. (Pubitemid 39361949)
96. Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006;65:654-61.
97. Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study. Arthritis Rheum 2006;54:1838-46. (Pubitemid 43877933)
98. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22. (Pubitemid 46698462)
99. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. The HORIZON Recurrent Fracture Trial: Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-809. (Pubitemid 350044800)
100. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41. (Pubitemid 32402100)
101. Ahrader SP, Raggucci KR. Parathyroid hormone (1-84) and treatment of osteoporosis. Ann Pharmacother 2005;39:1511-6.
102. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68. (Pubitemid 38133766)
103. Reginster JY, Felsenberg D, Boonen S, Diez-Perez A, Rizzoli R, Brandi ML, et al. Effects of long term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis, results of five year, randomizes, placebo-controlled trial. Arthritis and Rheumatism 2008;58:1687-95. (Pubitemid 351847521)
104. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-22. (Pubitemid 40686329)
105. Rabenda V, Hanssens L, De Ceulaer F, Reginster JY. Is there any interest in combining treatments in osteoporosis? Curr Rheumatol Rev 2005;1:49-55.
106. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. New Engl J Med 2003;249:1207-15. (Pubitemid 37152030)
107. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, et al. One year alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005;353:555-65. (Pubitemid 41138937)
108. Writing Group for the Women's Health Initiative Investigators. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women. JAMA 2002;288:321-33.
109. Writing Group for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post menopausal women. JAMA 1998;280:605-18.
110. Reid IR, Ames RW, Evans MC, Gamble GD, 1Sharpe SJ. Effect of calcium supplementation on bone loss in postmenopausal women. N Engl J Med 1993;328:460-4. (Pubitemid 23056435)
111. Gillepsie WJ, Avenell A, Henry DA, O'Connell DL, Robertson J. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2001;1:CD000227.
112. Chestnut CH 3rd, Silverman S, Adriano K, Genant H, Gimona A, Harris S, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The PROOF study. Am J Med 2000;109:267-76.
113. Clarke B, Khosla S. New and emerging treatment for osteoporosis. Mayo Clin Endocrinol Update 2008;3:2.